Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of wedelolactone in preparation of medicine and health care product for preventing and/or treating herpes virus infection

A technology of herpes virus infection and wecarolide, which is applied in the field of medicine and achieves the effects of inhibiting virus proliferation, interfering with virus adsorption, and having good market application prospects.

Pending Publication Date: 2022-01-04
THE AFFILIATED HOSPITAL OF QINGDAO UNIV +1
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the effect of wedelolide on simple viral infection has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of wedelolactone in preparation of medicine and health care product for preventing and/or treating herpes virus infection
  • Application of wedelolactone in preparation of medicine and health care product for preventing and/or treating herpes virus infection
  • Application of wedelolactone in preparation of medicine and health care product for preventing and/or treating herpes virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] Embodiment 1: the effect of wedelolide inhibiting herpes simplex virus in vitro

[0036] 1. Experimental method

[0037] 1.1 Cytotoxicity test of wedelolide

[0038] The cytotoxicity of wedelolide was determined on three different cells. Three kinds of cells, Vero, Hela, and Hep-2, were inoculated in 96-well plates until they were covered with a single layer. 50 μM, 25 μM, 12.5 μM or 300 μM, 150 μM, 175 μM, 37.5 μM, 18.75 μM) were added to 96-well plate, and each concentration was replicated three times, and a blank control group was set at the same time. Cells were placed at 37°C in 5% CO 2 After culturing in a constant temperature cell incubator for 24 hours, discard the drug, add 4% paraformaldehyde to fix at room temperature for 15 minutes, absorb and discard, add 5% crystal violet to stain at room temperature for 15 minutes, wash and dry, and measure A with a microplate reader. 540nm value.

[0039] Cell survival rate = test group A 540nm / Negative control g...

Embodiment 2

[0058] Embodiment 2: the mechanism of action of wedelolide against HSV

[0059] 1. Experimental method

[0060] 1.1 Indirect immunofluorescence test

[0061] Inoculate Vero cells on a 3.5 cm glass-bottom dish, and when the cells grow to a density of 30% to 40%, treat HSV-1 with wedelolide (final concentration 10 μM) according to the four different modes of action in 1.2 of Example 1 (MOI= 1), cultured in a 37°C incubator for 8 hours; then washed the cells with PBS, fixed with 4% paraformaldehyde at room temperature for 15 minutes, washed with PBS for 2 minutes, permeabilized with 0.25% Triton X-100 for 10 minutes, washed with PBS for 2 minutes, and washed with 2% BSA in Block at 37°C for 1 hour, wash with PBS three times, add ICP5 antibody (1:100 dilution) and incubate at 4°C for 16 hours, add FITC-coupled secondary antibody and incubate at 4°C for 4 hours after washing, wash three times, treat with DAPI for 10 minutes, and perform co-treatment after washing. Images were foc...

Embodiment 3

[0083] Example 3: The effect of Werethrin on HSV-infected mice

[0084] 1. Experimental method

[0085] 1.1 Experimental modeling

[0086] All the mice used in the present invention conform to the guidelines for humane treatment of experimental animals of the Ministry of Science and Technology of China (vgkfcz-2006-398). BALB / c female mice aged 3-4 weeks, weighing 14-15g, were randomly divided into 5 groups: blank control group, virus control group, positive drug (aciclovir 10 mg / kg / day) group, and the The high-dose (5 mg / kg / day) group of esters and the low-dose (2.5 mg / kg / day) group of isthrin. The drug was inoculated by nasal drip, and the drug was administered 4 hours after the drug was administered, and the drug was administered continuously for 5 days.

[0087] 1.2 Mouse detection

[0088] The mice were dissected 72 hours after exposure, and the lungs and spinal cords of the mice were taken to verify the anti-HSV-1 effect of the drug in vivo by plaque test and real-ti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of wedelolactone in preparation of a medicine and a health care product for preventing and / or treating herpes virus infection. Experiments prove that wedelolactone has an inhibitory activity effect on herpes simplex virus infection, that is, wedelolactone has anti-HSV-1 and HSV-2 activity, and is relatively low in toxicity. Wedelolactone can significantly inhibit expression of related proteins and mRNA of HSV-1 and HSV-2, has obvious dose dependence, and has the best effect at the early stage after HSV infection, namely 2-4 h. Wedelolactone achieves the effect of blocking herpes virus infection by directly inactivating virus particles or intervening the replication process after viruses enter cells and inhibiting virus proliferation, and the wedelolactone can reduce the virus load in mouse tissues on the in-vivo animal level. Therefore, wedelolactone has the potential of being developed into a novel anti-HSV preparation of targeted virus particles.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of wedelolide in the preparation of medicines and health care products for preventing and / or treating herpes virus infection. Background technique [0002] Herpes virus is an enveloped double-stranded DNA virus belonging to the herpesviridae family, the most typical of which is herpes simplex virus, which is mainly divided into type 1 (HSV-1) and type 2 (HSV-2). Infection in the population is very common, 80% - 90% of the initial infection is recessive infection, most of them have no obvious symptoms, among which HSV-1 infection causes skin damage, usually limited to the oral cavity, nasal cavity and eye level, while HSV-2 infection , Infection is most common in parts such as genital skin and mucous membranes. Current FDA-approved antiviral agents for herpes viruses mainly involve nucleoside analogs, such as acyclovir (ACV) and penciclovir, which mainly inhibi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61P31/22A23L33/10
CPCA61K31/366A61P31/22A23L33/10A23V2002/00A23V2200/30
Inventor 郝翠王伟王兆琦姚如永
Owner THE AFFILIATED HOSPITAL OF QINGDAO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com